Filing Analysis
Pulmonx Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders elected three Class III directors, ratified the appointment of BDO USA, P.C. as the independent auditor, and approved executive compensation on an advisory basis.
📋 Key Facts
- Annual Meeting held on June 4, 2026, with 77.29% of outstanding shares (32,645,270 shares) represented.
- Elected Class III directors: Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr.
- BDO USA, P.C. ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation approved on a non-binding advisory basis with 17,196,362 votes in favor.
Pulmonx Corporation reported its financial results for the first fiscal quarter ended March 31, 2026. The announcement was made via a press release on April 29, 2026, and furnished to the SEC under Item 2.02.
📋 Key Facts
- The company reported financial results for the first quarter of 2026 on April 29, 2026.
- The reporting period for the results ended on March 31, 2026.
- The filing includes Exhibit 99.1, which is the full press release titled 'Pulmonx Reports First Quarter 2026 Financial Results'.
- The report was signed by Derrick Sung, Ph.D., who serves as both Chief Operating Officer and Chief Financial Officer.
Pulmonx Corporation entered into a $60 million senior secured term loan facility with Perceptive Credit Holdings, drawing an initial $40 million to refinance existing debt. The agreement includes revenue-based milestones for additional funding and the issuance of 1,000,000 warrants to the lender.
🚩 Red Flags
- High cost of capital with a minimum interest rate of 10.75% plus fees.
- Revenue-based covenants and milestones create pressure on commercial performance.
- Dilutive warrant issuance of 1,000,000 shares with potential for more upon future draws.
- Significant prepayment penalties ranging from 2% to 10% within the first four years.
📋 Key Facts
- Initial borrowing of $40.0 million on March 2, 2026, with up to $20.0 million additional available in two tranches based on revenue milestones ($92.5M and $100M TTM).
- Interest rate is set at 1-month SOFR (minimum 3.75%) plus a 7.00% margin, with a PIK option for 2.00% of the margin for the first 36 months.
- The facility matures on March 2, 2031, and carries a minimum liquidity covenant of $4.0 million.
- Issued 1,000,000 warrants to Perceptive with an exercise price of $1.92 per share (25% premium to 10-day VWAP).
- Proceeds were used to repay and terminate the existing CIBC Credit Agreement without early termination penalties.
Pulmonx Corporation reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished under Item 2.02.
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025
- The report was filed and dated March 4, 2026
- The filing includes Exhibit 99.1, which is the official press release of the earnings
- The document was signed by Derrick Sung, Ph.D., who serves as both Chief Operating Officer and Chief Financial Officer